Synthesis and identification of small molecules that potently induce apoptosis in melanoma cells through G1 cell cycle arrest

Journal of the American Chemical Society

Volumn 127, Issue 24, 2005, Pages 8686-8696

  Dothager, Robin S ^a   Putt, Karson S ^a   Allen, Brittany J ^a   Leslie, Benjamin J ^a   Nesterenko, Vitaliy ^a   Hergenrother, Paul J ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; DNA; ENZYMES; SYNTHESIS (CHEMICAL); TOXICITY;

CHEMOTHERAPEUTIC TREATMENTS; MALIGNANT MELANOMA; MELANOMA CELLS; PROLIFERATION;

CELLS;

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRIPHENYLMETHYLAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER DIAGNOSIS; CANCER RESISTANCE; CANCER STAGING; CELL CYCLE; CELL CYCLE G1 PHASE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DNA SYNTHESIS; DRUG DETERMINATION; DRUG EFFICACY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MELANOMA CELL; MITOSIS; MOUSE; NONHUMAN; SURVIVAL TIME;

AMIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW CELLS; CELL LINE, TUMOR; G1 PHASE; HUMANS; MELANOMA; NF-KAPPA B; TERPHENYL COMPOUNDS;

EID: 20944433279     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja042913p     Document Type: Article

References (49)

1. Hanahan, D.; Weinberg, R. A. Cell 2000, 100, 57-70.
2. Makin, G.; Dive, C. Trends Mol. Med. 2003, 9, 251-255.
3. Ehlert, J. E.; Kubbutat, M. H. Onkologie 2001, 24, 433-440.
4. Zornig, M.; Hueber, A.; Baum, W.; Evan, G. Biochim. Biophys. Acta 2001, 1551, F1-F37.
5. Jordan, P.; Carmo-Fonsecab, M. Cell. Mol. Life Sci. 2000, 57, 1229-1235.
6. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Pharmacol. Rev. 2004, 56, 185-229.
7. Schwartz, P. S.; Waxman, D. J. Mol. Pharmacol. 2001, 60, 1268-1279.
8. Clifford, B.; Beljin, M.; Stark, G. R.; Taylor, W. R. Cancer Res. 2003, 63, 4074-4081.
9. Jordan, M. A.; Wilson, L. Nature Rev. Cancer 2004, 4, 253.
10. Adjei, A. A.; Rowinsky, E. K. Cancer Biol Ther. 2003, S1, S5-S15.
11. McGovern, V. J.; Balch, C. M.; Milton, G. W. In Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide; Lippincott, Williams & Wilkins: Philadelphia, 1985; pp 29-42.
12. Jemal, A.; Thomas, A.; Murray, T.; Thun, M. CA Cancer J. Clin. 2002, 52, 23-47.
13. Helmbach, H.; Rossmann, E.; Kern, M. A.; Schadendorf, D. Int. J. Cancer 2001, 93, 617-622.
14. Serrone, L.; Zeuli, M.; Sega, F. M.; Cognetti, F. J. Exp. Clin. Cancer Res. 2000, 19, 21-34.
15. Soengas, M. S.; Lowe, S. W. Oncogene 2003, 22, 3138-3151.
16. Middleton, M. R.; Lorigan, P.; Owen, J.; Ashcroft, L.; Lee, S. M.; Harper, P.; Thatcher, N. Br. J. Cancer 2000, 82, 1158-1162.
17. Schadendorf, D.; Worm. M.; Algermissen, B.; Kohlmus, C. M.; Czarnetzki, B. M. Cancer 1994, 73, 103-108.
18. Anderson,C. M.; Buzaid, A. C.; Legha, S. S. Oncology 1995, 9, 1149-1154.
19. Lev, D. C.; et al. J. Clin. Oncol. 2004, 22, 2092-2100.
20. Soengas, M. S.; et al. Nature 2001, 409, 207-211.
21. Grossman, D.; McNiff, J. M.; Li, F.; Altieri, D. C. J. Invest. Dermatol. 1999, 113, 1076-1081.
22. Cannon-Albright, L. A.; et al. Science 1992, 258, 1148-1152.
23. Fountain, J. W.; et al. Proc. Natl. Acad. Sci. 1992, 89, 10557-10561.
24. Huang, S.; DeGuzman, A.; Bucana, C. D.; Fidler, I. J. Clin. Cancer Res. 2000, 6, 2573-2581.
25. Makarov, S. S. Mol. Med. Today 2000, 6, 441-448.
26. Nesterenko, V.; Putt, K. S.; Hergenrother, P. J. J. Am. Chem. Soc. 2003, 125, 14672-14673.
27. Nguyen, J. T.; Wells, J. A. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 7533-7538.
28. Hwang, S. Y.; et al. Int. J. Oncol. 2003, 22, 151-157.
29. Kumar, R.; Sauroja, I.; Punnonen, K.; Jansen, C.; Hemminki, K. Genes Chromosomes Cancer 1998, 23, 273-277.
30. Szakacs, G.; et al. Cancer Cell 2004, 6, 129-137.
31. Amiri, K. I.; Horton, L. W.; LaFleur, B. J.; Sosman, J. A.; Richmond, A. Cancer Res. 2004, 64, 4912-4918.
32. Groopman, J. E.; Itri, L. M. J. Natl. Cancer Inst. 1999, 91, 1616-1634.
33. Konstantinov, S. M.; Topashka-Ancheva, M.; Benner, A.; Berger, M. R. Int. J. Cancer 1998, 77, 778-786.
34. de Graaff, M.; Maliepaard, M.; Pluim, D.; Floot, B. J.; Slaper-Cortenbach, I. C.; Schellens, J. H. Anticancer Drugs 1999, 10, 213-218.
35. LoRusso, P. M.; et al. Invest. New Drugs 1999, 16, 287-296.
36. Oredipe, O. A.; Furbert-Harris, P. M.; Laniyan, I.; Griffin, W. M.; Sridhar, R. Internation. Immunopharm. 2003, 3, 1537-1547.
37. Cyclophosphamide is activated in vivo to 4-hydroperoxycyclophosphamide (4-HC); however, both cyclophosphamide and 4-HC have been used in cell culture toxicity experiments. For an example of the recent uses of cyclophosphamide in cell culture experiments, please see: Rzeski, W.; et al. Ann. Neurol. 2004, 56, 351-360.
38. Blatt, N. B.; Glick, G. D. Bioorg. Med. Chem. 2001, 9, 1371-1384.
39. Cossarizza, A.; Baccarani-Contri, M.; Kalashnikova, G.; Franceschi, C. Biochem. Biophys. Res. Commun. 1993, 197, 40-45.
40. Satyamoorthy, K.; Bogenrieder, T.; Herlyn, M. Trends Mol. Med. 2001, 7, 191-194.
41. Monks, N. R.; Biswas, D. K.; Pardee, A. B. J. Cell Biochem. 2004, 92, 646-650.
42. Aggarwal, B. B. Cancer Cell 2004, 6, 203-208.
43. Joyce, D.; Albanese, C.; Steer, J.; Fu, M.; Bouzahzah, B.; Pestell, R. G. Cytokine Growth Factor Rev. 2001, 12, 73-90.
44. Bours, V.; Dejardin, E.; Goujon-Letawe, F.; Merville, M. P.; Castronovo, V. Biochem. Pharmacol. 1994, 47, 145-149.
45. Sunwoo, J. B.; Chen, Z.; Dong, G.; Yeh, N.; Crowl Bancroft, C.; Sausville, E.; Adams, J.; Elliott, P.; Van Waes, C. Clin. Cancer Res. 2001, 7, 1419-1428.
46. Rajkumar, S. V.; Richardson, P. G.; Hideshima, T.; Anderson, K. C. J. Clin. Oncol. 2005, 23, 630-639.
47. Massague, J. Nature 2004, 432, 298-306.
48. Seto, C. T.; Whitesides, G. M. J. Am. Chem. Soc. 1993, 115, 905-916.
49. Bollyky, L. J.; Whitman, R. H.; Clarke, R. A.; Rauhut, M. M. J. Org. Chem. 1967, 32, 1663-1667.